<DOC>
	<DOCNO>NCT00493155</DOCNO>
	<brief_summary>This study determine maximum tolerate dose , assess safety , tolerability pharmacokinetics R1530 administer orally patient advance metastatic solid tumor . R1530 administer daily 14 day start dose ; dose escalate subsequent cohort patient , satisfactory assessment safety tolerability previous dose , maximum tolerate dose reach . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study R1530 Patients With Advanced Solid Tumors .</brief_title>
	<detailed_description />
	<criteria>adult patient , &gt; =18 year age ; cancer amenable curative treatment ( ie advance and/or metastatic ) ; measurable evaluable disease ; adequate cardiac , hepatic renal function . patient know CNS metastasis ; serious cardiovascular illness medical condition ; prior chemotherapy , radiotherapy immunotherapy within 28 day start treatment , hormone therapy within 14 day start treatment ; inability swallow oral medication , impair gastrointestinal absorption .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>